balomenib   Click here for help

GtoPdb Ligand ID: 13734

Synonyms: ZE63-0302
Compound class: Synthetic organic
Comment: The chemical structure for balomenib was derived from WHO proposed INN list 132 (Feb 2025), in which it is listed as a menin inhibitor with antineoplastic potential. An internet search aligns the INN with the clinical candidate ZE63-0302 (Eilean Therapeutics). ZE63-0302 is described as an oral inhibitor of the menin-KMT2A interaction, which is a validated anti-tumour mechanism. ZE63-0302 is designed to retain activity against menin inhibitor resistance mutations, and it also has more a favourable safety profile with regard to QTc prolongation and cardiotoxicity than preceeding menin inhibitors.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 96.56
Molecular weight 617.67
XLogP 2.35
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC1=C(C=CC2=C1C=C(C#N)N2C[C@@H]3CNC(=O)CO3)CN4CCC5(CC4)CN(C5)C6=NC=NC7=CC=C(C=C76)CC(F)(F)F
Isomeric SMILES CC1=C2C=C(N(C2=CC=C1CN3CCC4(CN(C4)C5=NC=NC6=CC=C(C=C56)CC(F)(F)F)CC3)C[C@@H]7CNC(CO7)=O)C#N
InChI InChI=1S/C33H34F3N7O2/c1-21-23(3-5-29-26(21)11-24(13-37)43(29)16-25-14-38-30(44)17-45-25)15-41-8-6-32(7-9-41)18-42(19-32)31-27-10-22(12-33(34,35)36)2-4-28(27)39-20-40-31/h2-5,10-11,20,25H,6-9,12,14-19H2,1H3,(H,38,44)/t25-/m0/s1
InChI Key GTFGTNVSMRVPEN-VWLOTQADSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Balomenib (ZE63-0302) is a clinical candidate for the treament of acute myeloid leukemia (AML) with KMT2A rearrangements or NPM1 mutations.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06780124 Сlinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of ZE63-0302 in Healthy Volunteers Phase 1 Interventional Eilean Therapeutics